Angle has achieved a significant milestone in commercializing its proprietary cell separation system, Parsortix, with first research use sales announced in December. Important development news from its H116 results included Angle’s decision to seek FDA approval for Parsortix in breast cancer, which adds the potential for a second major clinical application, and further positive key opinion leader (KOL) evaluations of Parsortix with a third peer-reviewed article accepted for publication.
24 Feb 2016
Progress with FDA and first sales in the spotlight
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Progress with FDA and first sales in the spotlight
ANGLE plc (AGL:LON) | 13.0 0.1 6.1% | Mkt Cap: 33.9m
- Published:
24 Feb 2016 -
Author:
Jonas Peciulis -
Pages:
5
Angle has achieved a significant milestone in commercializing its proprietary cell separation system, Parsortix, with first research use sales announced in December. Important development news from its H116 results included Angle’s decision to seek FDA approval for Parsortix in breast cancer, which adds the potential for a second major clinical application, and further positive key opinion leader (KOL) evaluations of Parsortix with a third peer-reviewed article accepted for publication.